Retatrutide

{{Short description|Chemical compound}}

{{drugbox

| drug_name = Retatrutide

| image = Retatrutide.svg

| width = 280

| IUPAC_name = L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha -aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-Lleucyl-L-alpha -aspartyl-L-lysyl-N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-Lphenylalanyl-L-isoleucyl-L-alpha -glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-alpha -glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide

| synonyms = LY-3437943

| CAS_number = 2381089-83-2

| ChemSpiderID =

| ChEMBL = 5095485

| PubChem =

| UNII = NOP2Y096GV

| smiles =

| StdInChI =

| StdInChIKey =

}}

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).{{cite journal | vauthors = Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z | display-authors = 3 | title = LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept | journal = Cell Metabolism | volume = 34 | issue = 9 | pages = 1234–1247.e9 | date = September 2022 | pmid = 35985340 | doi = 10.1016/j.cmet.2022.07.013|doi-access=free| s2cid = 251675508 }} It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.{{cite press release|title=Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight |url=https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal |publisher=Eli Lilly| website= investor.lilly.com| date=26 June 2023|access-date=3 July 2023}}{{cite news|title=Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients|first=Annika Kim|last=Constantino|url=https://www.cnbc.com/2023/06/26/eli-lilly-obesity-drug-helped-patients-lose-weight.html|work= CNBC.com |date=26 June 2023|access-date=3 July 2023}}{{cite journal | vauthors = Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML | title = Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial | journal = The New England Journal of Medicine | date = June 2023 |display-authors= 3| volume = 389 | issue = 6 | pages = 514–526 | pmid = 37366315 | doi = 10.1056/NEJMoa2301972| s2cid = 259260926 }} Free access subject to registration. In the trial, the participants who received the highest dose (12 mg) showed a mean weight reduction of 24.2% after 48 weeks.